Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Several efficacy/mechanism details are inconsistent or not supported by the provided label excerpts. Many safety statements (rates, reversibility, risk factors) are not supported with the specific percentages or comparative claims provided. However, some liver-test monitoring and ALT/AST testing timing are supported.
Category Scores
Accurate Statements
Persistent elevations (>3 times ULN occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received LIPITOR in clinical trials.
5.2 Liver Dysfunction: “Persistent elevations (>3 times ULN occurring on 2 or more occasions) ... occurred in 0.7% of patients...”
Lipitor can cause elevated liver enzymes (ALT and AST).
5.2 Liver Dysfunction: monitoring recommendations for increases in ALT or AST; 6.1: “hepatic enzyme increase” and alanine aminotransferase increase.
Monitoring liver enzymes is emphasized for patients taking Lipitor.
5.2 Liver Dysfunction: “It is recommended that liver function tests be performed prior to and at 12 weeks following both the initiation... and any elevation of dose...”
Patients taking Lipitor should have their liver enzymes checked before starting the medication.
5.2 Liver Dysfunction: “performed prior to ... initiation of therapy...”
Unsupported Statements
Lipitor (atorvastatin) is a statin that works by inhibiting the production of cholesterol in the liver.
The provided label excerpt states mechanism as inhibition of HMG-CoA reductase and cholesterol biosynthesis, but does not specifically say “inhibiting the production of cholesterol in the liver.” (12.1 provided, but not the exact phrasing/location).
Most cases of Lipitor-associated liver problems are reversible when the medication is discontinued.
No such reversibility statement is present in the provided label excerpts.
Liver enzyme abnormalities occurred in approximately 1.6% of patients taking Lipitor.
No 1.6% value appears in the provided label excerpts.
The rate of liver enzyme elevations in patients taking Lipitor was reported as 0.5%.
No 0.5% value is provided in the provided label excerpts for liver enzyme elevations (0.7% is provided for persistent >3x ULN elevations).
Lipitor can cause jaundice.
No “jaundice” term appears in the provided adverse reactions excerpts.
Lipitor can cause fatigue.
Fatigue is listed in postmarketing experience, but this is only partially aligned with the excerpt scope; however the word “fatigue” is explicitly present under 6.2 Postmarketing Experience. This claim is therefore supported rather than unsupported; included here only if exact inclusion is required elsewhere (but label does include fatigue).
Lipitor can cause loss of appetite.
No “loss of appetite” term appears in the provided adverse reactions excerpts.
Lipitor can cause nausea and vomiting.
Nausea is listed as a common adverse reaction leading to discontinuation (6.1), but vomiting is not mentioned in the provided excerpts.
Lipitor can cause abdominal pain.
No “abdominal pain” term appears in the provided adverse reactions excerpts.
Individuals with pre-existing liver disease may be at higher risk of liver problems with Lipitor.
The label excerpt includes contraindication for active liver disease, but does not provide a “higher risk” statement for pre-existing liver disease within the provided sections.
Individuals with a history of liver damage may be at higher risk of liver problems with Lipitor.
No such “history”/risk statement appears in provided excerpts.
Patients taking other medications that can affect the liver may be at higher risk of liver problems with Lipitor.
Provided interaction excerpt addresses myopathy/muscle risk with CYP3A4 inhibitors/fibric acid/niacin/cyclosporine; it does not specifically address liver-problem risk.
Older adults may be at higher risk of liver problems with Lipitor.
No age-related liver risk statement is present in the provided excerpts.
People with kidney disease may be at higher risk of liver problems with Lipitor.
Provided label excerpt states renal disease does not affect plasma concentrations nor LDL-C reduction (12.3), but does not state increased liver-problem risk with kidney disease.
In severe cases, liver problems with Lipitor can lead to liver failure.
“hepatic failure” appears in postmarketing experience, but the provided excerpts do not explicitly link liver problems to progression to liver failure in “severe cases.” (6.2 mentions hepatic failure as an adverse reaction.)
Liver failure has been reported in approximately 1 in 100,000 patients taking Lipitor.
No incidence (e.g., 1 in 100,000) for hepatic failure/liver failure appears in the provided label excerpts.
The risk of liver problems with Lipitor is relatively low but not zero.
No such qualitative risk phrasing is present in the provided excerpts.
Patients taking Lipitor should have their liver enzymes checked at regular intervals thereafter.
Provided label specifies testing prior to initiation and at 12 weeks following initiation and after any elevation of dose; it does not state “regular intervals thereafter.”
Contradictions
Low
AI Statement
The rate of liver enzyme elevations in patients taking Lipitor was reported as 0.5%.
Label Reference
5.2 Liver Dysfunction: persistent >3x ULN elevations on 2+ occasions occurred in 0.7%. Provided excerpt does not support 0.5% for liver enzyme elevations.
Important Omissions
The label’s recommended liver function test timing: prior to and at 12 weeks following initiation, and at any elevation of dose; plus guidance to reduce dose/withdraw if ALT/AST increase >3x ULN persists.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple quantitative claims (1.6%, 0.5%, 1 in 100,000) and qualitative risk statements are not supported by the provided label excerpts. The statement about “regular intervals thereafter” is broader than the label timing provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several safety/statistical claims (incidence rates, reversibility, progression to liver failure, and risk-factor statements) are not supported by the provided label excerpts; monitoring language is imprecise versus the label’s specific timing.
Suggested Improvement
Replace unsupported incidence/risk-factor/reversibility statements with the specific label-supported information: persistent transaminase elevations occurred in 0.7% in trials; perform liver function tests prior to initiation and at 12 weeks after initiation and after dose increases; reduce dose or withdraw if ALT/AST increase >3x ULN persists.